Home > Knowledge Center > Webinar: State of the Art in Clinical Transporter DDI Evaluation

Webinar: State of the Art in Clinical Transporter DDI Evaluation

Webinar Download

Originally Hosted:
Thursday, June 13, 2019
11:30am – 12:30pm EDT

State of the Art in Clinical Transporter DDI Evaluation

This presentation summarized the state-of-the-art in transporters in drug development based on four recent ITC3 whitepapers (Clin Pharmacol Ther 104, October 2018).

  • Transporters in drug development based on four recent ITC3 whitepapers
  • Overview of emerging transporters of clinical relevance
  • Best practice in design of clinical DDI studies through recent advances
  • Consideration for optimal selection of clinical probe drugs, including future potential utility of transporter biomarkers

Absorption Systems partnered with GSK to provide you with the most relevant and applicable research in Transporter DDI Evaluations

 

This presentation is based on the data highlighted in four recent publications by the International Transporter Consortium.

These four publications are available for download below:

DABIGATRAN ETEXILATE & DIGOXIN COMPARISON AS CLINICAL PROBE SUBSTRATES FOR EVALUATION OF PGP INHIBITION
 
CLINICAL PROBES & ENDOGENOUS BIOMARKERS AS SUBSTRATES FOR TRANSPORTER DRUG-DRUG INTERACTION EVALUATION
 
ITC COMMENTARY ON METFORMIN CLINICAL DRUG-DRUG INTERACTION STUDY DESIGN THAT ENABLES AN EFFICACY- AND SAFETY- BASED DOSE ADJUSTMENT DECISION
 
TRANSPORTERS IN DRUG DEVELOPMENT: 2018 ITC RECOMMENDATIONS FOR TRANSPORTERS OF EMERGING CLINICAL IMPORTANCE
 

Presenter:
Maciej J. Zamek-Gliszczynski, PhD
Senior Fellow and Director, DMPK, GlaxoSmithKline

Register Here: